Drug Trial Radar · NCT07529951
Study of ZE74-0282 in Patients With JAK2 V617F- or Calreticulin-Mutated Hematologic Disorders
Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Jun 1, 2026
Primary completion
Sep 30, 2028
Study completion Dec 30, 2028
Sponsor
- Lead sponsor
- Eilean TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Apr 14, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase 1 study will evaluate ZE74-0282 in adults with polycythemia vera or myelofibrosis with a JAK2 V617F or calreticulin mutation who have received prior therapy or have declined prior therapy. The main objectives are to determine the maximum tolerated dose and/or recommended Phase 2 dose, characterize safety and tolerability, describe pharmacokinetics and pharmacodynamics, and assess preliminary anti-disease activity. In Part 1, participants will receive escalating oral doses of ZE74-0282 using a Rolling-6 dose-finding design. Once-daily and twice-daily dosing schedules may be evaluated, including protocol-specified step-up dosing. In Part 2, participants will be randomized to one of two selected expansion doses to further evaluate safety, pharmacokinetics, pharmacodynamics, and preliminary activity. ZE74-0282 is administered as an oral powder for suspension in continuous 28-day treatment cycles.
Conditions
- Polycythemia Vera (PV)
- Myelofibrosis (MF)
Interventions
ZE74-0282Drug
ZE74-0282 is an oral powder for suspension supplied in 25 mg and 75 mg sachets. It is administered orally with noncarbonated water once daily (QD) or twice daily (BID), as assigned/selected by cohort, in continuous 28-day treatment cycles. Dosing is performed in a fasting state: no food or drink other than water for at least 2 hours before and 1 hour after dosing. The starting dose is 150 mg QD. If supported by healthy-volunteer data, 150 mg QD and 75 mg BID cohorts may be enrolled concurrently. Step-up dosing may be used based on emerging safety, pharmacokinetic, and pharmacodynamic data. For protocol-specified patients assigned to 150 mg BID, the step-up schedule may be 25 mg BID on Day 1, 50 mg BID on Day 2, 75 mg BID on Day 3, 100 mg BID on Day 4, 125 mg BID on Day 5, and 150 mg BID from Day 6 onward. Treatment may continue for up to 24 cycles unless discontinued earlier according to protocol criteria.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Dose-Limiting ToxicitiesTime frame: Cycle 1, Day 1 through Day 28 (each cycle is 28 days)
- Determination of the Recommended Phase 2 Dose (RP2D)Time frame: During Part 2 dose expansion, using participant data collected from the first dose through approximately 5 months.
Locations
2 sites in 2 countries. Site status is shown where the registry gives one.
Linear Clinical Research Ltd
Nedlands, Western Australia, Australia · Recruiting
Republican Specialized Hematology Scientific and Practical Medical Center
Tashkent, Uzbekistan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.